Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur Child Adolesc Psychiatry ; 27(1): 79-88, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28685401

RESUMEN

Animal studies suggest that prenatal vitamin D status may affect fetal brain growth. However, human studies are scarce with conflicting results. We aimed to investigate the association of maternal 25-hydroxyvitamin D [25(OH) D] levels with multiple neurodevelopmental outcomes at 4 years of age. We included 487 mother-child pairs from the prospective pregnancy cohort, "Rhea" in Crete, Greece. Maternal serum 25(OH) D concentrations were measured at the first prenatal visit (13 ± 2.4 weeks). Cognitive functions at 4 years were assessed by means of the McCarthy Scales of Children's Abilities. Behavioral difficulties were assessed by means of Strengths and Difficulties Questionnaire and Attention Deficit Hyperactivity Disorder Test. Children of women in the high 25(OH) D tertile (>50.7 nmol/l) had 37% decreased number of hyperactivity-impulsivity symptoms (IRR 0.63, 95% CI 0.39, 0.99, p trend = 0.05) and 40% decreased number of total ADHD-like symptoms (IRR 0.60, 95% CI 0.37, 0.95, p trend = 0.03) at 4 years of age, compared to children of women in the low 25(OH) D tertile (<38.4 nmol/l), after adjustment for several confounders. Similar associations were found with the hyperactivity/inattention score of the SDQ questionnaire. Children of mothers with high 25(OH) D levels had also fewer total behavioral difficulties (beta-coeff: -1.25, 95% CI -2.32, -0.19) and externalizing symptoms (beta-coeff: -0.87, 95% CI -1.58, -0.15) at preschool age. The observed associations were stronger in girls than in boys (p for interaction < 0.1). No association was observed between maternal 25(OH) D concentrations and cognitive function in preschoolers. Our results suggest that high maternal vitamin D levels in early pregnancy may protect against behavioral difficulties, especially ADHD-like symptoms at preschool age.


Asunto(s)
Encéfalo/fisiopatología , Madres/psicología , Vitamina D/uso terapéutico , Adulto , Animales , Niño , Preescolar , Estudios de Cohortes , Femenino , Grecia , Humanos , Masculino , Embarazo , Estudios Prospectivos
2.
Eur Child Adolesc Psychiatry ; 26(6): 703-714, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28050707

RESUMEN

Studies have suggested an association between maternal obesity pre-pregnancy and gestational diabetes (GDM) with impaired offspring neurodevelopment, but it is not clear if these associations are explained by shared familiar characteristics. We aimed to assess the associations of maternal and paternal obesity, maternal glucose intolerance in early pregnancy and GDM, with offspring neurodevelopment at 4 years of age. We included 772 mother-child pairs from the "Rhea" Mother-Child cohort in Crete, Greece. Data on maternal/paternal body mass index (BMI) and maternal fasting serum samples for glucose and insulin measurements were collected at 12 weeks of gestation. GDM screening was performed at 24-28 weeks. Neurodevelopment at 4 years was assessed using the McCarthy Scales of Children's Abilities. Behavioral difficulties were assessed by Strengths and Difficulties Questionnaire and Attention Deficit Hyperactivity Disorder Test. Multivariate linear regression analyses showed that maternal obesity was associated with a significant score reduction in general cognitive ability (ß-coeff -4.03, 95% CI: -7.08, -0.97), perceptual performance (ß-coeff -4.60, 95% CI: -7.74, -1.47), quantitative ability (ß-coeff -4.43, 95% CI: -7.68, -1.18), and executive functions (ß-coeff -4.92, 95% CI: -8.06, -1.78) at 4 years of age, after adjustment for several confounders and paternal BMI. Maternal obesity was also associated with increased behavioral difficulties (ß-coeff 1.22, 95% CI: 0.09, 2.34) and ADHD symptoms (ß-coeff 4.28, 95% CI: 1.20, 7.36) at preschool age. Paternal obesity maternal glucose intolerance in early pregnancy and GDM was not associated with child neurodevelopment. These findings suggest that maternal obesity may impair optimal child neurodevelopment at preschool age independently of family shared characteristics.


Asunto(s)
Diabetes Gestacional/psicología , Obesidad/complicaciones , Preescolar , Estudios de Cohortes , Femenino , Grecia , Humanos , Masculino , Madres , Embarazo , Factores de Riesgo
3.
PLoS One ; 10(5): e0126327, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25970502

RESUMEN

CONTEXT: Maternal pre-pregnancy obesity may increase the risk of childhood obesity but it is unknown whether other metabolic factors in early pregnancy such as lipid profile and hypertension are associated with offspring cardiometabolic traits. OBJECTIVE: Our objective was to investigate whether fasting lipid, glucose, and insulin levels during early pregnancy and maternal pre-pregnancy weight status, are associated with offspring adiposity measures, lipid levels and blood pressure at preschool age. DESIGN AND METHODS: The study included 618 mother-child pairs of the pregnancy cohort "Rhea" study in Crete, Greece. Pregnant women were recruited at the first prenatal visit (mean: 12 weeks, SD: 0.7). A subset of 348 women provided fasting serum samples for glucose and lipid measurements. Outcomes measures were body mass index, abdominal circumference, sum of skinfold thickness, and blood pressure measurements at 4 years of age. A subsample of 525 children provided non-fasting blood samples for lipid measurements. RESULTS: Pre-pregnancy overweight/obesity was associated with greater risk of offspring overweight/obesity (RR: 1.83, 95%CI: 1.19, 2.81), central adiposity (RR: 1.97, 95%CI: 1.11, 3.49), and greater fat mass by 5.10 mm (95%CI: 2.49, 7.71) at 4 years of age. These associations were more pronounced in girls. An increase of 40 mg/dl in fasting serum cholesterol levels in early pregnancy was associated with greater skinfold thickness by 3.30 mm (95%CI: 1.41, 5.20) at 4 years of age after adjusting for pre-pregnancy BMI and several other confounders. An increase of 10 mmHg in diastolic blood pressure in early pregnancy was associated with increased risk of offspring overweight/obesity (RR: 1.22, 95%CI: 1.03, 1.45), and greater skinfold thickness by 1.71 mm (95% CI: 0.57, 2.86) at 4 years of age. CONCLUSIONS: Metabolic dysregulation in early pregnancy may increase the risk of obesity at preschool age.


Asunto(s)
Tejido Adiposo/fisiopatología , Adiposidad/fisiología , Glucemia/metabolismo , Metaboloma , Obesidad Infantil/fisiopatología , Tejido Adiposo/metabolismo , Adulto , Peso al Nacer , Presión Sanguínea , Índice de Masa Corporal , Preescolar , Colesterol/sangre , Estudios de Cohortes , Ayuno , Femenino , Grecia , Humanos , Masculino , Obesidad Infantil/sangre , Embarazo , Factores de Riesgo , Grosor de los Pliegues Cutáneos , Circunferencia de la Cintura
4.
J Histochem Cytochem ; 61(6): 433-43, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23456824

RESUMEN

The AKT-mTOR pathway is activated in diabetic nephropathy. Renin-angiotensin system modulators exert beneficial effects on the diabetic kidney. We explored the action of losartan on AKT-mTOR phosphorylation in glomeruli and podocytes. Diabetes mellitus was induced to Sprague-Dawley rats by streptozotocin. Five months later, the rats were commenced on losartan and euthanized 2 months later. Kidneys were processed for immunofluorescence studies. Glomeruli were isolated for Western blot analysis. Diabetes increased activated forms of AKT and mTOR both in glomeruli and podocytes. In diabetic rats, losartan decreased phosphorylated/activated forms of AKT (Thr308) and mTOR (Ser2448) in glomeruli but decreased only activated mTOR in podocytes. However, in both glomeruli and podocytes of healthy animals, an inverse pattern was evident. In conclusion, a new body of evidence indicates the differential activation of AKT-mTOR in glomeruli and podocytes of healthy and diabetic animals in response to losartan.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Nefropatías Diabéticas/tratamiento farmacológico , Modelos Animales de Enfermedad , Glomérulos Renales/efectos de los fármacos , Losartán/farmacología , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Animales , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/patología , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/patología , Glomérulos Renales/metabolismo , Glomérulos Renales/patología , Losartán/administración & dosificación , Masculino , Fosforilación/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Serina-Treonina Quinasas TOR/metabolismo
5.
Hormones (Athens) ; 11(2): 210-4, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22801569

RESUMEN

OBJECTIVE: To describe a rare case of occult (<1 cm in diameter) medullary thyroid carcinoma (MTC) in a 45-year-old woman, presenting as an asymptomatic mediastinal mass. DESIGN: The diagnostic methodology included laboratory measurements of relevant biochemical and hormonal parameters including calcitonin (CT), carcinoembryonic antigen (CEA) and chromogranin A, and imaging techniques including ultrasound (U/S), computed tomography (C/T), magnetic resonance imaging (MRI) and radio labeled somatostatin analog ((111)In-DTPA-octreotide). RESULTS: Chest CT revealed a mediastinal mass measuring 5 cm in diameter abutting the right thyroid lobe. CEA was elevated and an association with thyroid malignancies was considered. CT was found to be markedly elevated, pointing to the diagnosis of MTC metastatic to the mediastinum. The patient underwent total thyroidectomy, lymph node dissection and removal of the mediastinal mass. Histological examination revealed MTC of the right thyroid lobe measuring 0.5 cm, metastatic to regional and superior mediastinal lymph nodes. CONCLUSIONS: Occult MTC can infrequently present as an asymptomatic mediastinal mass. Elevated serum CT and CEA along with imaging techniques leads to the correct diagnosis and surgical management of the disease.


Asunto(s)
Carcinoma Medular/secundario , Neoplasias del Mediastino/secundario , Glándula Tiroides/patología , Neoplasias de la Tiroides/patología , Antígeno Carcinoembrionario/metabolismo , Carcinoma Neuroendocrino , Femenino , Humanos , Metástasis Linfática , Persona de Mediana Edad , Tomógrafos Computarizados por Rayos X
6.
Clin Endocrinol (Oxf) ; 69(4): 542-8, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18331604

RESUMEN

OBJECTIVE: To describe our 3-year experience in the long-term efficacy and safety of percutaneous ethanol injection therapy (PEIT), as an alternative to surgery for the management of patients with primary hyperparathyroidism (p-HPT). DESIGN: Prospective study with a mean follow-up of 19.6 +/- 10.6 months. PATIENTS: Our study population included 19 consecutive high risk patients with p-HPT, who met the criteria for surgery. MEASUREMENTS: Under ultrasonic guidance, ethanol (95%) was injected into parathyroid glands with a volume of >or= 0.15 cm(3). With the aim of normalizing intact parathormone (iPTH) values, repeated ethanol injections were carried out, in an interval of 2 weeks, until normalization of iPTH was reached or until no residual blood supply was detected by ultrasound in the gland. Biochemical parameters were monitored throughout the study. RESULTS: At 6-month follow-up, normalization of iPTH levels (10-65 ng/l) was achieved in 11 (58%) patients (responders). Of the eight remaining patients (nonresponders), six patients had reduced (but not normalized) iPTH levels and two patients required parathyroid surgery. Seventeen (11 responders and 6 nonresponders) of the 19 patients (89.5%) became normocalcaemic (serum Ca 200 ng/l. The only complication was a transient dysphonia noticed in three patients. CONCLUSIONS: PEIT is a safe and effective nonsurgical treatment for patients with p-HPT, who are unsuitable for surgical intervention.


Asunto(s)
Terapias Complementarias/métodos , Etanol/administración & dosificación , Hiperparatiroidismo Primario/tratamiento farmacológico , Hiperparatiroidismo Primario/cirugía , Adenoma/complicaciones , Adenoma/diagnóstico , Adenoma/tratamiento farmacológico , Adenoma/cirugía , Administración Cutánea , Anciano , Contraindicaciones , Etanol/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Hiperparatiroidismo Primario/diagnóstico , Hiperparatiroidismo Primario/etiología , Inyecciones Intralesiones , Masculino , Persona de Mediana Edad , Glándulas Paratiroides/diagnóstico por imagen , Hormona Paratiroidea/sangre , Neoplasias de las Paratiroides/complicaciones , Neoplasias de las Paratiroides/diagnóstico , Neoplasias de las Paratiroides/tratamiento farmacológico , Neoplasias de las Paratiroides/cirugía , Paratiroidectomía , Pronóstico , Resultado del Tratamiento , Ultrasonografía
7.
Hormones (Athens) ; 4(1): 18-27, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16574628

RESUMEN

As human beings venture into space in the 21st century, they will be confronted with a "hypodynamic" and thus hostile environment for the bone homeostasis, that could potentially compromise their mobility in general and skeletal strength in particular after landing. From this point of view, space flight studies are especially interesting and intriguing models for scientists. Space studies, however, must not only overcome enormous technical problems but are also limited in size and frequency. Therefore, ground-based models have also been developed to evaluate the effects of skeletal unloading. The most popular model for human studies is prolonged bed rest with normal volunteers, although studies with paraplegics have also been undertaken. In animals, the hindlimb elevation (tail suspension) model simulates space flight models and is well tolerated by the animals with minimal evidence of stress. Although negative calcium balance and bone loss have been observed in all the aforementioned models of skeletal unloading, the exact mechanism(s) by which this occurs are still unknown and mainly speculative.


Asunto(s)
Densidad Ósea/fisiología , Huesos/fisiología , Osteoporosis/prevención & control , Vuelo Espacial , Ingravidez , Animales , Calcio/metabolismo , Modelos Animales de Enfermedad , Homeostasis/fisiología , Humanos , Osteoporosis/etiología , Ratas , Ingravidez/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA